A Phase 1 Dose Escalation and Expansion Study of ABL501, a Bispecific Antibody of PD-L1 and LAG-3 as a Single Agent in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
Latest Information Update: 02 Aug 2024
At a glance
- Drugs ABL 501 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors ABL Bio
- 31 Jul 2024 Status changed from recruiting to completed.
- 29 Jan 2024 Planned End Date changed from 31 Jul 2024 to 31 Dec 2024.
- 29 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 30 Jun 2024.